Spritam Approval History
Spritam (levetiracetam) is a 3D printed drug product used as adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy.
Development History and FDA Approval Process for Spritam
|Aug 3, 2015||FDA Approves Spritam (levetiracetam) as the First 3D Printed Drug Product|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.